Levetiracetam (All indications) - Medication and Pregnancy KB

Levetiracetam (All indications)

Neonatal medical care

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S15220 R62421	Bromley (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023	Neonatal special care admission	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.55 [0.23;1.34] ^C excluded (control group)	8/70 20/106	28	70		ref
S15219 R62408	Bromley (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023	Neonatal special care admission	during pregnancy (anytime or not specified)	prospective cohort	unexposed, sick	Adjustment: No	1.59 [0.52;4.83] ^C	8/70 6/80	14	70		ref
S12618 R47571	Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021	Need for special care nursery or neonatal intensive care unit (NICU) admission	at least 1st trimester	prospective cohort	unexposed, disease free excluded	Adjustment: No	0.87 [0.36;2.09] ^C excluded (control group)	10/87 13/100	23	87		ref
S12615 R47553	Van Marter (Levetiracetam) (Controls unexposed, sick), 2021	Need for special care nursery or neonatal intensive care unit (NICU) admission	at least 1st trimester excluded	prospective cohort	unexposed, sick	Adjustment: No	0.78 [0.15;4.00] ^C excluded (exposition period)	10/87 2/14	12	87		ref
S8986 R30515	Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	exposed to other treatment, sick excluded	Adjustment: No	0.09 [0.00;2.41] ^C excluded (control group)	0/10 2/7	2	10		ref
S8987 R30525	Aydin (Levetiracetam) (Controls unexposed, sick), 2020	Neonatal intensive care unit (NICU)	throughout pregnancy	retrospective cohort	unexposed, sick	Adjustment: No	0.41 [0.02;9.43] ^C	0/10 2/22	2	10		ref
S9029 R30783	Bank (Levetiracetam) (Mixed indications), 2017	Admission to neonatal intensive care unit (NICU) or Special Care Nursery	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick	Adjustment: No	0.83 [0.08;8.24] ^C	1/7 6/36	7	7		ref
S8983 R30476	Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	exposed to other treatment, sick excluded	Adjustment: No	1.08 [0.22;5.26] ^C excluded (control group)	2/12 24/154	26	12		ref
S8984 R30488	Artama (Levetiracetam) (Controls unexposed, disease free), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, disease free excluded	Adjustment: Yes	2.37 [0.52;10.92] excluded (control group)	2/12 49,612/689,482	49,614	12		ref
S8985 R30500	Artama (Levetiracetam) (Controls unexposed, sick), 2013	Admission to neonatal care unit	3rd trimester	population based cohort retrospective	unexposed, sick	Adjustment: Yes	1.86 [0.39;8.92]	2/12 152/1,708	154	12		ref
					Total	4 studies	1.40 [0.62;3.15]		177	99
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Mixed indications; 4: Levetiracetam) (Controls unexposed, sick;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Sub-groups analysis using all included studies

excluded 8983, 8984, 8986, 12618, 15220